We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Inflammation Test Developed Predicts Cardiovascular Disease

By LabMedica International staff writers
Posted on 03 Nov 2016
Print article
Image: A diagram of cell cytokine signaling response (Photo courtesy of Stanford University).
Image: A diagram of cell cytokine signaling response (Photo courtesy of Stanford University).
Chronic inflammation, a decline in immune responsiveness, and reduced cardiovascular function are all associated with aging, but the relationships among these phenomena remain unclear.

An assessment blending several measures of immune-cell responsiveness predicted cardiovascular problems in individuals who likely would have slipped under the radar. A blood test produces a single number that strongly predicts the development of the world’s most prevalent medical disorder: cardiovascular disease.

An international team of scientists led by those at Stanford University School of Medicine (Stanford, CA, USA) longitudinally profiled a total of 84 signaling conditions in 91 young and older adults and observed an age-related reduction in cytokine responsiveness within four immune cell lineages, most prominently T cells. Testing for levels of C-reactive protein (CRP), a circulating protein linked to inflammation, has been shown to further enhance the prediction of cardiovascular risk, even among patients with normal cholesterol levels. A CRP reading is relatively simple to get, requiring only a blood draw and relatively straightforward laboratory tests.

The new test developed is more complicated but appears to have superior diagnostic value to either the cholesterol or CRP test. Rather than testing circulating inflammatory proteins, it tests for the response of immune cells themselves to inflammation, a signal that appears to be more stable and hence a more robust diagnostic. In the study, it was able to detect early cardiovascular irregularities in otherwise asymptomatic individuals. The phenotype can be partially explained by elevated baseline levels of phosphorylated STAT (pSTAT) proteins and a different response capacity of naive versus memory T cell subsets to interleukin 6 (IL-6), interferon α (IFN-α), and, to a lesser extent, IL-21 and IFN-γ.

When immune cells from young people were stimulated with certain cytokines, the activation levels of STAT proteins skyrocketed. When the same thing was done to immune cells from old people, STAT-protein activity increased a lot less. The investigators blended 15 separate cytokine-responsiveness measurements to generate a single number called a cytokine response score (CRS). This measure, which varied considerably among different older adults, was quite stable from year to year for any given individual.

A higher CRS is better, as it indicates a more-responsive immune system and lower background inflammation. The team found that cytokine response scores were inversely correlated with clinical signs of atherosclerosis and with two measures associated with the heart’s ability to relax between beats. Importantly, the borderline subjects also had low cytokine response scores.

Mark M Davis, PhD, professor of microbiology and immunology and the senior author of the study, said, “For too many men experiencing a heart attack or stroke, the first observed hint of cardiovascular risk is their death. The CRS may be a useful proxy for healthy aging and its predictive accuracy in cardiovascular disease further substantiates the inflammatory underpinnings of that prevalent, age-related condition.” The study was published on October 13, 2016, in the Cell Systems.

Related Links:
Stanford University School of Medicine

Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Vaginitis Test
Allplex Vaginitis Screening Assay
New
Silver Member
Total Hemoglobin Monitoring System
GREENCARE Hb

Print article

Channels

Clinical Chemistry

view channel
Image: The research team has developed the uCR-Chip device to enhance kidney function testing (Photo courtesy of University of Manitoba)

Low-Cost Portable Screening Test to Transform Kidney Disease Detection

Millions of individuals suffer from kidney disease, which often remains undiagnosed until it has reached a critical stage. This silent epidemic not only diminishes the quality of life for those affected... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The UV absorbance spectrometer being used to measure the absorbance spectra of cell culture samples (Photo courtesy of SMART CAMP)

Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures

Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.